Truist Financial restated their buy rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $4.00 price target on the stock. Several other brokerages have also issued reports on HOOK. Royal Bank of Canada reissued an outperform rating and issued a $7.00 […]
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has experienced a decline in its stock price by -3.20 compared to its previous closing price of 0.67. However, the company has seen a fall of -7.55% in its stock price over the last five trading days. GlobeNewsWire reported 2023-08-03 that NEW YORK and VIENNA, Aust
Hookipa Pharma (NASDAQ:HOOK – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.01), reports. The company had revenue of $2.68 million during the quarter, compared to the consensus estimate of $3.54 million. Hookipa Pharma had a […]
Hookipa Pharma Inc (NASDAQ:HOOK – Get Free Report) was the recipient of a large decline in short interest during the month of July. As of July 15th, there was short interest totalling 805,900 shares, a decline of 11.5% from the June 30th total of 910,600 shares. Currently, 1.2% of the company’s stock are short sold. […]
Hookipa Pharma Inc (NASDAQ:HOOK – Get Rating) was the target of a large drop in short interest in May. As of May 31st, there was short interest totalling 68,600 shares, a drop of 78.2% from the May 15th total of 314,900 shares. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is […]